Designing a QSAR for ER Binding. QSAR Xenobiotic ER Binding Altered Protein Expression Altered Hormone Levels, Ova-testis Chg 2ndry Sex Char, Altered.

Slides:



Advertisements
Similar presentations
Perspectives from EPA’s Endocrine Disruptor Screening Program
Advertisements

Dosimetry in Risk Assessment and a bit More Mel Andersen McKim Conference QSAR and Aquatic Toxicology & Risk Assessment June 27-29, 2006.
Evaluating Existing in vitro Endocrine Data Jeff Pregenzer, Director of Endocrine Studies, CeeTox.
An Evaluation of Models to Predict the Activity of Environmental Estrogens Candice M. Johnson and Rominder Suri, Ph.D.,P.E. NSF Water and Environmental.
IQF Framework for QSAR 1. Identify Plausible Molecular Initiating Events 2. Design Database for Abiotic Binding Affinity/Rates 3. Explore Linkages in Pathways.
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
Session III: Assessing Cumulative Effects of Endocrine Active Substances 9:15 - 9:30 Introduction” Rick Becker (Session Chair and Panel Moderator) 9:30.
Priority-setting for the Endocrine Disruptor Screening Program: Pesticide Active Ingredients Penelope A. Fenner-Crisp Office of Pesticide Programs U.S.
National Pesticide Program A New Toxicology Testing Paradigm: Meeting Common Needs Steven Bradbury, Director Environmental Fate and Effects Division Office.
CONFERENCE ON “ FOOD ADDITIVES : SAFETY IN USE AND CONSUMER CONCERNS“ JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY NAIROBI, 24 JUNE 2014.
Endocrine Screening – Phase 1 TSCA 8(e) and FIFRA 6(a)(2) Requirements A. Michael Kaplan, Ph.D. December 13, 2010 A. Michael Kaplan & Associates, LLC
1 Development & Evaluation of Ecotoxicity Predictive Tools EPA Development Team Regional Stakeholder Meetings January 11-22, 2010.
What Do Toxicologists Do?
Criteria for Screens— Review of the EDSTAC Recommendations Presentation to the EDMVS July 23, 2002.
ILSI Risk Science Institute Acrylamide Toxicity: Research to Address Key Data Gaps Presented by Dr. Stephen S. Olin ILSI Risk Science Institute.
Application of Toxicology Databases in Drug Development (Estimating potential toxicity) Joseph F. Contrera, Ph.D. Director, Regulatory Research and Analysis.
The Role of Research in the Business of the Environmental Protection Agency Steven Bradbury, Director Environmental Fate & Effects Division Office of Pesticide.
1 Discussion of the 2006 Inventory Update Reporting Data December 12, 2006 Nhan Nguyen U.S. EPA.
Status of the U.S. Endocrine Disruptor Screening Program (EDSP) Status of the U.S. Endocrine Disruptor Screening Program (EDSP) September
Chapter 13. The Impact of Genomics on Antimicrobial Drug Discovery and Toxicology CBBL - Young-sik Sohn-
Office of Pesticide Programs 21st Century Screening Assessment of Pesticides – A Regulatory View Vicki Dellarco, Ph.D. Senior Science Advisor Office of.
(IAQ). What is Risk Assessment? Risk assessment: provides information on the health risk Characterizes the potential adverse health effects of human exposures.
Dr. Manfred Wentz Director, Hohenstein Institutes (USA) Head, Oeko-Tex Certification Body (USA) AAFA – Environmental Committee Meeting November 10, 2008.
VISUALIZATION OF ADVERSE EFFECT PATHWAYS Hristo Aladjov.
Applying Adverse Outcome Pathway Concepts to ER-mediated Effects Pat Schmieder US Environmental Protection Agency Office of Research and Development National.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Mike Comber Consulting TIMES-SS Assessment of skin sensitisation hazard Presented on behalf of the TIMES-SS consortia.
2 n McKim Workshop on Reducing Data Redundancy in Cancer Assessment | 8 – 10 May 2012 | Baltimore, MD Highlighting the Need for AOPs in Streamlining Hazard.
Predicting Estrogen Receptor Binding within Categories Rick Kolanczyk Environmental Protection Agency Office of Research and Development National Health.
Dose-Response for Reproductive Effects of ER Binders P. Schmieder R. Johnson.
0 Focusing on the Adverse Outcomes of ER-mediated Pathways Rodney Johnson ORD/MED McKim Conference September 16-18, 2008.
Mike Comber TIMES-SS Application of Reactivity Principles in Screening for Skin Sensitisers Presented on behalf of the TIMES-SS consortia & International.
QSAR Foundation Goals Facilitate promising QSAR technologies for setting priorities (TIMES-SS, Multipath, ASTER, OECD Toolbox) Encourage the expansion.
Public Health Assessment Process Jack Hanley, M.P.H. Environmental Health Scientist Agency for Toxic Substances and Disease Registry.
Toxicological Knowledge Base (a Definition) Response Dose “ An in computero aggregated set of the most germane literature citations and biological activity.
McKim Conference on Predictive Toxicology
The Adverse Outcome Pathway (AOP) for Skin Sensitisation (SS): How We Got Here and Where We are Going 1 T. W. Schultz Professor Emeritus The University.
The McKim Conferences for the Strategic Use of Testing Gitchee Gumee Conference Center Duluth, Minnesota June 27-29, 2006.
QSAR in CANCER ASSESSMENT PURPOSE and AGENDA Gilman Veith Duluth MN May 19-21, 2010.
Chapter 15.3 Risk Assessment 2002 WHO report: “Focusing on risks to health is the key to preventing disease and injury.” risk assessment—process of evaluating.
POLLUTION BY XENOBIOTICS : BIOMARKERS FOR EARLY DETECTION OF POLLUTION EFFECTS Ibon Cancio EUSKALHERRIKOUNIBERTSITATEA UNIVERSITY OF THE BASQUE COUNTRY.
T. W. Schultz Presented at the McKim Conference September 17, 2008.
OECD’s work on Adverse outcome pathways
Barcelona April, 2008 Overview of the QSAR Application Toolbox Gilman Veith International QSAR Foundation Duluth, Minnesota.
McKim Conference on Predictive Toxicology The Inn of Lake Superior Duluth, Minnesota September 25-27, 2007 Narcosis as a Reference Gilman Veith.
NUATRC/TCEQ Air Toxics Workshop October Air Toxics Air Toxics: What We Know, What we Don’t Know, and What We Need to Know Human Health Effects –
McKim Conference on Predictive Toxicology The Inn of Lake Superior Duluth, Minnesota September 16-18, 2008 Toxicity Pathways as an Organizing Concept Gilman.
Criteria for Inherently toxic (iT) in CEPA, UNEP Proposed iT criteria for non-human organisms –aquatic acute effects levels of < 1 mg/L –above 1 mg/L.
RISK DUE TO AIR POLLUTANTS
McKim Workshop on Strategic Approaches for Reducing Data Redundancy in Cancer Assessment Duluth, MN, USA 19 May, 2010.
McKim Conference on Predictive Toxicology The Inn of Lake Superior Duluth, Minnesota September 25-27, 2007 Toxicity Pathways as an Organizing Concept Gilman.
Perspective on the current state-of-knowledge of mode of action as it relates to the dose response assessment of cancer and noncancer toxicity Jennifer.
QSAR in CANCER ASSESSMENT PURPOSE and AGENDA Gilman Veith Duluth MN May 19-21, 2010.
Key Concepts on Health Risk Assessment of Chemical Mixtures.
Cumulative Risk Assessment: A Critical Step Forward in Human Health Protection Deborah A. Cory-Slechta Department of Environmental Medicine University.
Acute Toxicity Studies Single dose - rat, mouse (5/sex/dose), dog, monkey (1/sex/dose) 14 day observation In-life observations (body wt., food consumption,
General Concepts in QSAR for Using the QSAR Application Toolbox
Endocrine Disruptor Screening and Testing: An Industry Update
Drug Discovery &Development
QSAR Application Toolbox: Step 12: Building a QSAR model
FIFRA SAP Meeting February 2, 2010
General Concepts in QSAR for Using the QSAR Application Toolbox
Use of Quantitative Structure-Activity Relationships (QSAR) to Predict Chemical Toxicity in Aquatic Organisms P. Schmieder US EPA Mid-Continent Ecology.
Potential Role for Endocrine Disruptor Expert Systems in Investigating ‘Endocrine System-Epigenome’ Interactions P. Schmieder EPA, ORD, NHEERL, MED-Duluth,
Visualization of Adverse effect pathways
OAK CREEK Toxicology & Risk Assessment Consulting
Decision Contexts in a Changing Toxicology Paradigm
Ovanes Mekenyan, Milen Todorov, Ksenia Gerova
What is environmental toxicology ?
EFSA’s Chemical Hazards Database
Presentation transcript:

Designing a QSAR for ER Binding

QSAR Xenobiotic ER Binding Altered Protein Expression Altered Hormone Levels, Ova-testis Chg 2ndry Sex Char, Altered Repro. Defining Toxicity Pathways Across Levels of Biological Organization: Direct Chemical Binding to ER Toxicological Understanding Risk Assessment Relevance In vivo Assays In vitro Assays MOLECULAR CELLULAR TISSUE/ORGAN INDIVIDUAL Skewed Sex Ratios, Altered Repro. POPULATION

QSARs for Prioritization What: Prioritize chemicals based on ability to bind ER (plausibly linked to adverse effect) Determine which untested chemicals should be tested in assays that will detect this activity, prioritized above very low risk chemicals for this effect Demonstrate how QSARs are built, for complex problems, and are useful to regulators/risk assessors Why: To provide EPA with predictive tools for prioritization of testing requirements and enhanced interpretation of exposure, hazard identification and dose-response information Develop the means to knows what to test, when to test, how FQPA - Little of no data for most inerts/antimicrobials; short timeline for assessments;

Lessons Learned from early EPA exercise 1) High quality data is critical and should not be assumed –Models can be no better than the data upon which they are formulated –Assays should be optimized to determine the adequacy for the types of chemicals found within regulatory lists Assumption that assays adequate for high-medium potency chemicals will detect low potency chemicals warrants careful evaluation –Mechanistic understanding should be sought; new information incorporated when available Assumption that ER binding mechanism was well understood warrants careful evaluation 2) Defining a regulatory domain is not a trivial exercise –Assumption that ~6000 HPVCs would represent additional regulatory domains needs careful evaluation; regulatory lists need to be defined –Structure verification is needed for all chemicals on regulatory lists 3) Determining coverage of regulatory domain is non-trivial –Using a TrSet of “found” data (which included few chemicals structures found in regulatory domain) proved to be inadequate to complete QSAR development –QSAR development is an iterative process that requires systematic testing within regulatory domain of interest

Prioritizing EDC Risk Assessment Questions within Large Chemical Inventories Developing Predictive Models is an Iterative Process High Quality Data Strategic Chemical Selection Evaluate TrSet Coverage Of Inventory QSAR Model Structural Requirements Regulatory Acceptance Criteria QSAR Libraries Modeling Engine Estimation of Missing Data Analogue Identification Prioritization/Ranking Elucidate Toxicity Pathway (e.g., ER binding to repro effects) Evaluate Regulated Chemicals For Ability to Initiate Pathway (e.g., ER binding training set (TrSet)) Initial TrSet (CERI/RAL) Undefined Chemical Inventory

Prioritizing EDC Risk Assessment Questions within Large Chemical Inventories Developing Predictive Models is an Iterative Process High Quality Data Strategic Chemical Selection Evaluate TrSet Coverage Of Inventory QSAR Model Structural Requirements Regulatory Acceptance Criteria QSAR Libraries Modeling Engine Estimation of Missing Data Analogue Identification Prioritization/Ranking Elucidate Toxicity Pathway (e.g., ER binding to repro effects) Evaluate Regulated Chemicals For Ability to Initiate Pathway (e.g., ER binding training set (TrSet)) Initial TrSet (MED) OPP Inventory Directed/designed Training Set

High quality data is critical –Assays should be optimized to determine the adequacy for the types of chemicals on the relevant regulatory list Test assays on low potency chemicals Test to solubility HOW to test?

MED Database Focus on Molecular Initiating Event 1) rtER binding is assessed using a standard competitive binding assay; -chemicals are tested to compound solubility limit in the assay media; 2) equivocal binding curves are interpreted using a higher- order assay (gene activation and vitellogenin mRNA production in metabolically competent trout liver slices)

rat ER vs rainbow trout ER for 55 chemicals

Concentration dependent vitellogenin (VTG) gene expression as VTGmRNA production in male rainbow trout liver slices exposed to p-t-octylphenol for 48 hrs (Mean + STDS, n=5).

4-n-butylaniline (Mean + STDS, n=5)

resorcinol sulfide (Mean + STDS, n=5; dashed line indicates toxic concentrations).

Data collected needs to address the problem Expand training set to cover types of chemicals on the relevant regulatory lists WHAT to test?

Prioritizing EDC Risk Assessment Questions within Large Chemical Inventories Developing Predictive Models is an Iterative Process High Quality Data Strategic Chemical Selection Evaluate TrSet Coverage Of Inventory QSAR Model Structural Requirements Regulatory Acceptance Criteria QSAR Libraries Modeling Engine Estimation of Missing Data Analogue Identification Prioritization/Ranking Elucidate Toxicity Pathway (e.g., ER binding to repro effects) Evaluate Regulated Chemicals For Ability to Initiate Pathway (e.g., ER binding training set (TrSet)) Initial TrSet (MED) OPP Inventory Directed/designed Training Set

2) Defining a regulatory domain is not a trivial exercise 3) Determining coverage of regulatory domain is non-trivial –Using a TrSet of “found” data (which included few chemicals structures found in regulatory domain) proved to be inadequate to complete QSAR development –QSAR development is an iterative process that requires systematic testing within regulatory domain of interest

Define the Problem: Food Use Pesticide Inerts List included: 937 entries -(36 repeats + 8 invalid CAS#) 893 entries 893 entries = 393 discrete non-discrete substances (44% discrete : 56% non-discrete) 393 discrete chemicals include: organics inorganics organometallics 500 non-discrete substances include: 147 polymers of mixed chain length 170 mixtures 183 undefined substances

Chemical Category TotalDiscreteDefined Mixtures PolymersUndefined Substance Food Use Inerts Antimicrobials Sanitizers Antimicrobials + Sanitizers HPV IUR Total Inerts* (OPP website, Aug 2004) Registered Pesticide Active Ingredients* OPP Chemical Inventories * Structure verification in progress

Prioritizing EDC Risk Assessment Questions within Large Chemical Inventories Developing Predictive Models is an Iterative Process High Quality Data Strategic Chemical Selection Evaluate TrSet Coverage Of Inventory QSAR Model Structural Requirements Regulatory Acceptance Criteria QSAR Libraries Modeling Engine Estimation of Missing Data Analogue Identification Prioritization/Ranking Elucidate Toxicity Pathway (e.g., ER binding to repro effects) Evaluate Regulated Chemicals For Ability to Initiate Pathway (e.g., ER binding training set (TrSet)) Initial TrSet (MED) OPP Inventory Directed/designed Training Set

Original ER Binding Training Sets Initial focus of ER binding data sets from 1990s : –Steroids, anti-estrogens (high potency binders) –Organochlorines –Alkylphenols CERI hER NCTR rER MED rtER Food Use Inerts Anti- microbial HPV Inerts HPV TSCA Steroid, Anti-E2, OrganoCl 150 (30%) 91 (40%) 372 (<1%) 2 (1%) 6 (1%) 178 (3%) Alkyl- phenols 35 (7%) 13 (6%) 223 (1%) 7 (3%) 6 (1%) 71 (1%) Covered groups as % of total 37%46%2%4%2%4%

Building New Training Sets New inventories –Food Use Inerts –Antimicrobials and Sanitizers –HPV inerts –Total Inerts –HPV TSCA chemicals CERI (hER) NCTR (rER) ORD- MED (rtER) Food Use Inerts A/SHPV Inerts HPV TSCA Acyclics3 (0.6%) 6 (2.6%) 22 (10%) 230 (59%) 121 (57%) 291 (65%) 2655 (41%) Aromatic Sulfates 4 (0.8%) 1 (0.4%) 1588 (22%) 6 (3%) 15 (3%) 347 (5%)

Prioritizing EDC Risk Assessment Questions within Large Chemical Inventories Developing Predictive Models is an Iterative Process High Quality Data Strategic Chemical Selection Evaluate TrSet Coverage Of Inventory QSAR Model Structural Requirements Regulatory Acceptance Criteria QSAR Libraries Modeling Engine Estimation of Missing Data Analogue Identification Prioritization/Ranking Elucidate Toxicity Pathway (e.g., ER binding to repro effects) Evaluate Regulated Chemicals For Ability to Initiate Pathway (e.g., ER binding training set (TrSet)) Initial TrSet (MED) OPP Inventory Directed/designed Training Set

QSAR Principles for ER interactions Chemical are “similar” if they produce the same biological action from the same initiating event –Not all chemicals bind ER in same way, i.e., not all “similar” –ER binders are “similar” if they have the same type of interaction within the receptor QSARs require a well-defined/well understood biological system; assay strengths and limitations understood QSARs for large list of diverse chemicals –require iterative process – test, hypothesize, evaluate, new hypothesis, test again, etc. –to gain mechanistic understanding to group similar acting chemicals; build model within a group

R 394 E 353 H 524 B B A A Estrogen binding pocket schematic representation C C T 347 C C J. Katzenellenbogen

R 394 E 353 H 524 C C T 347 HO OH CH 3 H HH H A A B B A-B Mechanism Distance = 10.8 for 17  -Estradiol

R 394 E 353 H 524 C C T 347 HO OH CH 3 H HH H A A B B A-B Mechanism Distance. Probability density. Based on 39 CERI Steroidal Structures 9.73<Distance<11.5 Akahori; Nakai (CERI)

R 394 E 353 H 524 T 347 B B A-C Mechanism Distance. Probability density. Based on 21 RAL A-C Structures 9.1 < Distance < 9.6 OH A A HO C C Katzenellenbogen

R 394 E 353 H 524 T 347 A A C C A-B-C Mechanism Distance. Probability density. Based on 66 RAL A-B-C Structures HO OH B B NN 11.5 < Distance < < Distance <8 Katzenellenbogen

R 394 E 353 H 524 C C T 347 A A B B A-B Mechanism HO OH 11.4 < Distance < 14.2 Distance. Probability density. Based on 59 RAL A-B Structures

Hypothesis testing Hypothesize structural parameter(s) associated with toxicity Select chemicals that satisfy the hypothesis Hypothesis: Chemicals with interatomic distance between O-atoms satisfying distance criteria for a binding type have the potential to bind ER based on electronic interactions. Test, and confirm or modify hypothesis

Because acyclics are > 50% of inventories, what is the possibility that any acyclics satisfy criteria of high affinity binding types? Selected acyclics for testing that met A_B distance; no binders found (charged cmpds – apparent binding but no activation) As suspected, most OPP chemicals could not be evaluated with the A_B or A_C mechanism models; Need to refine ER binding hypotheses to investigate additional binding types –Chemicals interact with ER in more than one way, influencing data interpretation and model development; –Need to group chemicals by like activity, then attempt to model as a group that initiate action through same chemical- biological interaction mechanism, and should have common features –Find common features and predict which other untested chemicals may have similar activity – prioritize for testing

High quality data is critical ER binding hypotheses refined –Chemicals interact with ER in more than one way, influencing data interpretation and model development HOW to interpret test results?

R 394 E 353 H 524 C C T 347 HO OH CH 3 H HH H A A B B A-B Mechanism Distance = 10.8 for 17  -Estradiol

Q Oxygen = Q Oxygen = HO OH CH 3 HH H A A B B

R 394 E 353 H 524 C C T 347 HO A A B B A Mechanism CH 3

R 394 E 353 H 524 C C T 347 A A B B B Mechanism H3CH3C NH 2

R 394 E 353 H 524 C C T 347 HO A A B B A Mechanism CH 3

H Q Oxygen = Q Oxygen = HO OH CH 3 HH H

Chemical Universe Contains Cycle Non binder (RBA< ) Yes Contains two or more nucleophilic Sites (O or N) Possible High Affinity, A-B; A-C; or A-B-C type binder Steric Exclusion Parameter Attenuation? Yes No High Binding Affinity A-B; A-C; or A-B-C type No Non binder Ex: Progesterone Corticossterone (RBA< ) Other Mechanisms A_Type Binder B_Type Binder No Non binder (RBA< ) Activity Range log KOW <1.4 Yes No Yes A B Low Affinity Binder A-B; A-C; or A-B-C type Undefined decision parameter? Yes No Classes with special structural rules Undefined decision parameter? Yes Significant Binding Affinity A or B type ? RBA=a*logP +b Non binder (RBA< ) RBA=a*logP +b Alkyl Phenols Benzoate Parabens Benzketones Anilines Phthalates No

Libraries of Toxicological Pathways ER Binding ER Transctivation VTG mRNA Vitellogenin Induction Sex Steroids Altered Reproduction/ Development Molecular Cellular Organ Individual Chemical 3-D Structure/ Properties Chemical 2-D Structure Structure Initiating Events Impaired Reproduction/Development Mapping Toxicity Pathways to Adverse Outcomes

Libraries of Toxicological Pathways Initiating Events Adverse Outcomes Mapping Toxicity Pathways to Adverse Outcomes

Acknowledgements: MED – J. Denny, R. Kolanczyk, B. Sheedy, M. Tapper; SSC – C. Peck; B. Nelson; T. Wehinger, B. Johnson; L. Toonen; R. Maciewski NRC Post-doc: H. Aladjov Bourgus University - LMC: O. Mekenyan, and many others Chemicals Evaluation Research Institute (CERI), Japan - Y. Akahori, N. Nakai EPA/NERL-Athens: J. Jones EPA/OPP: EFED - S. Bradbury, J. Holmes RD - B.Shackleford, P. Wagner AD - J. Housenger, D. Smegal HED – L. Scarano Mentors: G. Veith, L. Weber, and J.M. McKim, III